Best Sell-Side Advisor for Your Dental PE Sale In 2026

Key Takeaways

• A sell-side advisor represents the practice owner through valuation, marketing, and negotiation to improve price and terms in a DSO or private equity sale.

• Four common representation options exist: DIY, local generalist broker, multi-vertical advisor, and “free valuation” firms, each with specific trade-offs in experience, buyer access, and outcomes.

• Helpful selection criteria include dental-only focus, sell-side exclusivity, CPA-led diligence-grade valuation, rigorous buyer vetting, and a transaction rate that materially exceeds the 35–40% industry average.

• Competitive multi-buyer auctions often generate around 10 offers and can increase total transaction value by 30–100% compared to accepting a single unsolicited DSO offer.

• McLerran & Associates offers a free, confidential discovery call to help owners review options and choose a path that fits their goals. Schedule yours today.

Representation Options for a DSO or Private Equity Sale

Every dental practice owner who receives an unsolicited letter of intent (LOI) faces a central decision about representation. An LOI is a formal written offer from a buyer expressing interest in acquiring the practice.

That decision can shape the entire financial result. A practice owner usually sells once in a career. A DSO negotiates acquisitions every week. That asymmetry in experience, information, and leverage can be one of the main reasons representation choice affects value by seven figures.

Four categories of representation appear most often in the market today. Each category brings a different approach and a different range of likely outcomes.

Do-it-yourself (DIY). The owner negotiates directly with the buyer. No commission is paid, but the owner carries the full information disadvantage and has no competitive tension. DIY close rates can run as low as 15–20%, and the buyer effectively sets the valuation.

Local generalist broker. A local broker may assist but often knows only one or two DSO buyers. Market exposure stays limited, underwriting quality tends to be weaker, and DSOs usually bid less aggressively on deals from brokers who transact infrequently.

Multi-vertical sell-side advisor. These firms handle M&A across several healthcare verticals such as dental, veterinary, and ophthalmology. They bring deal experience but may not maintain a team focused solely on dental. That gap can mean less nuance on specialty dynamics and a shallower dental buyer pool.

“Free valuation” lead-generation firm. These firms offer a complimentary valuation as a lead magnet, then market the practice to a partial buyer list. Because the valuation is not diligence-grade, it often does not hold up under buyer review. Deals then get re-traded, which means renegotiated downward after the LOI is signed.

McLerran & Associates operates as a dental-only, sell-side-only advisor, representing practice owners exclusively and never buyers. The firm has roughly 2,000 successful practice sales, approximately $2 billion in closed transaction volume, and more than 10,000 practices evaluated over approximately 35 years.

How to Choose a Sell-Side Advisor for a DSO Sale

Advisor selection for a private equity or DSO transaction involves several practical factors that can influence the financial and personal outcome. The following points can be some of the most useful to review.

Dental-only focus. Advisors who work exclusively in dental understand how multiples and buyer demand differ across specialties, how valuations vary by region, and which DSOs are well-capitalized versus which have struggled after closing. Generalist advisors may not see these patterns as clearly.

Sell-side exclusivity. An advisor who also represents buyers carries a structural conflict of interest. A sell-side-only firm aligns its incentives with the practice owner’s outcome.

Valuation methodology. A diligence-grade, CPA-led EBITDA analysis forms the base of a defensible deal. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is adjusted through “add-backs,” which are discretionary or non-recurring expenses added back to earnings to reflect true profitability. Buyers distinguish between seller-side normalized EBITDA and buy-side quality-of-earnings reviews, often rejecting add-backs that are not well documented or transferable. Weak valuation work often gets re-traded after the LOI is signed.

Buyer pool and vetting rigor. The size and quality of the buyer pool can influence how much competitive tension the process creates. Advisors who have blacklisted poorly run DSOs help protect sellers from partnering with undercapitalized or operationally weak buyers.

Transaction rate. Industry close rates for brokered dental transactions average roughly 35–40%. A materially higher transaction rate usually reflects process discipline and valuation quality rather than luck.

Fee model. A paid, upfront valuation often signals that the advisor focuses on accuracy instead of using a free number as a marketing tool. Success fees tied to closing price help keep incentives aligned with the seller.

Schedule a free, confidential discovery call with McLerran & Associates to discuss your practice, your goals, and which path may serve you best.

Dental Practice EBITDA Multiples Private Equity 2026

EBITDA is the profitability metric that institutional buyers such as DSOs and private equity firms commonly use to value dental practices. The multiple applied to that EBITDA figure often drives enterprise value in a DSO transaction. That multiple varies by practice size, structure, specialty, and buyer type.

Based on triangulated data from multiple 2026 market sources, the following ranges reflect current conditions for general dental practices sold to PE-backed DSOs.

Single-doctor general dental practices often trade at approximately 4x–7x EBITDA, while practices with $1M–$3M EBITDA can transact at higher multiples with regional DSO add-on buyers. Practices with $3M–$5M EBITDA typically reach 9x–11x EBITDA with emerging platform or strategic acquirer buyers, while $5M+ EBITDA practices can reach 11x or higher in select platform-level private equity cases. Specialty practices such as oral surgery, orthodontics, and pediatric dentistry can command higher multiples than general dentistry, depending on size, geography, and buyer mix.

Several factors can move a practice’s multiple within these ranges. High provider concentration, where the selling owner generates a large share of collections, can lead buyers to adjust production before applying a multiple. A practice with substantial Medicaid revenue can experience multiple compression and a narrower buyer universe. A strong hygiene program often supports premium multiples and better DSO offers, because recurring hygiene visits signal a stable, transferable patient base.

Dental practice valuations stood at 5x to 11x EBITDA in mid-2026 and are expected to compress toward 4x to 6x over the next few years. That trend makes both timing and sale-process quality more consequential. The multiple any specific practice achieves depends on its own fundamentals, which a diligence-grade valuation is designed to quantify.

Find out what your practice may be worth. Schedule a free, confidential discovery call with McLerran & Associates and request a comprehensive practice valuation.

How Competitive Auctions Improve DSO Sale Outcomes

Dental practice buyers who approach owners directly usually assume they face no competition and have little reason to present their best offer upfront. A structured, multi-buyer auction process changes that dynamic.

McLerran & Associates typically runs a 45–60 day competitive bid process that generates around 10 offers per listing from a vetted pool of DSO and private equity buyers. The process narrows from initial offers to in-person meetings with the top one to three finalists. McLerran manages the competition and models each deal’s true economic value to the seller.

A competitive multi-buyer sales process in dental M&A often improves total transaction value by 30–100% over accepting a single unsolicited DSO offer. McLerran & Associates clients typically see valuations that sit materially above what owners report achieving on their own, largely because of the competitive tension that a structured auction creates.

Process mechanics matter as much as buyer count. McLerran prepares a marketing deck and a virtual data room, which is a comprehensive, organized repository of the practice’s financial and operational information, before going to market. Buyers then evaluate the same diligence-grade picture that should hold up through closing.

Rollover Equity and Earnout Pitfalls to Watch

In a DSO transaction, not all consideration usually arrives as cash at closing. In DSO-backed dental transactions, 60–80% of total deal value is commonly received at close, with the remainder structured as rollover equity and/or earnout provisions. Rollover equity means the selling dentist keeps a stake in the DSO and effectively becomes an investor in the acquiring organization.

That equity can sit at two levels. Joint-venture (JV) equity ties to the specific practice location and can offer distributions but a lower ceiling on upside. Holding-company equity ties to the entire DSO enterprise and usually offers no distributions but a higher potential ceiling if the DSO recapitalizes or sells. Form of consideration in DSO deals often includes 20–80% equity rollover or earnouts, which introduce post-close risk that many sellers discount relative to all-cash offers, since buyers control performance metrics and recapitalization timelines.

Partnering with an undercapitalized or poorly run DSO can put a significant share of the owner’s proceeds at risk. McLerran & Associates vets buyers like investments, helping owners review a DSO’s profitability, growth trajectory, leadership quality, and financial backing. DSOs known for poor post-close environments are blacklisted and do not reach the table.

Earnout terms, which tie a portion of the purchase price to future performance metrics, also benefit from careful negotiation. McLerran often pushes for non-punitive earnout structures, such as pro-rata provisions that pay most of the earnout even if a target is narrowly missed, and later start dates that account for the integration period.

2026 PE/DSO Market Update for Dental Practice Owners

The dental M&A market in 2026 features selective buying, higher buyer standards, and continued interest in well-prepared practices. 69% of DSOs surveyed indicated that their private equity sponsors expect a moderate or high increase in acquisition activity in 2026, with dental EBITDA multiples in 2026 ranging from 5x–12x depending on practice size and type, even as buyer selectivity has increased due to reduced supply of premium practices.

Deal structures in dental practice sales have shifted toward less cash at closing and more contingencies such as promissory notes and EBITDA maintenance requirements, with buyers increasingly requiring five-year employment agreements and sustained performance commitments from sellers.

Provider risk, clinical continuity, declining financial performance, and reimbursement exposure ranked as top reasons DSOs walked away from potential deals in the first half of 2026. This level of selectivity can make advisor preparation quality and valuation defensibility more influential than in earlier cycles.

Elevated interest rates have compressed debt-financeable multiples from 2021 peaks for single-office deals, while sponsor-backed platform multiples for high-quality assets have held up due to substantial PE dry powder, which refers to uncommitted capital available for investment. That combination has created a split outcome: well-prepared practices often command premium multiples, while marginal deals face longer timelines or fail to close.

Find the Right Advisory Fit for Your Practice

The table below compares the five primary categories of representation available to dental practice owners considering a DSO or private equity transaction. The data highlight a clear pattern: DIY and “free valuation” approaches tend to close fewer deals with weaker buyer vetting, while structured, dental-specific advisory processes close a much higher share of engagements with more offers and stronger diligence. Every figure is drawn from cited sources or McLerran & Associates’ documented track record.

Advisor Category	Transaction Rate	Offer Volume	Valuation Methodology	Buyer-Vetting Rigor
DIY / For-Sale-By-Owner	~15–20%	1 (the buyer who called)	Buyer-set, no independent analysis	None
Local Generalist Broker	Below industry average	1–2 known DSOs	Weak, often not diligence-grade	Minimal, limited buyer relationships
Multi-Vertical Advisor	Variable	Variable, not dental-specific	Variable, may lack dental EBITDA depth	Variable, not dental-focused
“Free Valuation” Firm	~35–40% (industry norm)	Partial buyer list	Free or back-of-napkin, often re-traded in diligence	Low, bad actors not consistently screened out
McLerran & Associates	~85–90%	~10 offers per listing	CPA-led, diligence-grade EBITDA that is designed not to re-trade	High, with poorly run DSOs blacklisted

McLerran & Associates is one of the few dental-specific firms that works both the private-buyer and DSO paths in roughly equal measure, with approximately a 50/50 split. That structure gives owners a genuine side-by-side comparison that single-lane brokers usually cannot provide. For owners in the $1.5M–$3M revenue range who could qualify for either path, that comparison can be one of the most valuable parts of the engagement.

How McLerran Models and Protects Your Outcome

Maximizing outcome in a dental practice sale involves more than chasing the highest headline number. The total economic result includes cash at close, the structure and quality of any rollover equity, earnout terms, post-close employment compensation, and tax treatment. Much of a DSO deal may qualify for long-term capital gains rates rather than ordinary income, which can materially affect net proceeds.

McLerran & Associates prepares multi-year, multi-structure financial forecasts that model what each path may net the owner over 3-, 5-, 7-, and 10-year horizons, conservatively assuming one recapitalization in years five to seven. That modeling allows owners to compare a private-buyer outcome, a DSO cash-plus-equity outcome, and the baseline of keeping the practice, side by side, with after-tax numbers instead of only headline figures.

Once exclusivity begins after an LOI is signed, sellers lose leverage because they have stopped engaging alternative buyers and the buyer controls the pace and framing of confirmatory diligence findings. McLerran’s quality-of-earnings defense, which means actively defending the EBITDA it underwrote when the buyer’s team reviews the numbers, and the reminder that other vetted bidders remain available, are two mechanisms that can help keep agreed value from eroding between LOI and close.

10 Questions to Ask Every Sell-Side Advisor

Before engaging any advisor for a dental practice sale, the questions below can surface meaningful differences in capability, alignment, and track record.

1. Do you represent buyers as well as sellers, or are you sell-side only?

2. Is your firm dental-specific, or do you work across multiple healthcare or business verticals?

3. How many dental practice transactions have you closed in the last 24 months, and what is your transaction rate?

4. Who specifically will lead my transaction, and what is their background, such as investment banking, DSO operations, or CPA?

5. Is your valuation CPA-led and diligence-grade, or is it a complimentary estimate used mainly to initiate the engagement?

6. How many offers does your process typically generate, and how long does the competitive bid process run?

7. How do you vet buyers, and have you blacklisted any DSOs, and on what basis?

8. Can you model my outcome across multiple deal structures and time horizons, including the baseline of not selling?

9. How do you defend the agreed valuation through due diligence if the buyer attempts to re-trade the deal?

10. Can you provide references from clients with practices of similar size and specialty who have closed in the last 12 months?

Conclusion

The dental M&A market in 2026 tends to reward preparation, competition, and experienced representation. A practice owner who accepts a single unsolicited offer without a structured process usually negotiates from a weaker position against buyers who complete multiple transactions each year. The gap between a single-offer outcome and a competitive auction with a diligence-grade valuation can often be measured in millions.

McLerran & Associates’ 35-year track record in dental-only, sell-side representation has positioned the firm to guide practice owners through both private-buyer and DSO paths in roughly equal measure. That dual-path view helps each client see the full picture before making one of the most consequential financial decisions of their career.

Schedule a free, confidential discovery call with McLerran & Associates. Call (512) 900-7989, email info@dentaltransitions.com, or visit dentaltransitions.com/contact-us to speak with an advisor about your practice, your goals, and your options, with no obligation and no pressure.

Frequently Asked Questions

What does a sell-side advisor actually do in a dental practice sale, and why does it matter?

A sell-side advisor represents the practice owner, not the buyer, through every stage of the transaction. Core responsibilities include building a defensible valuation, preparing marketing materials, running a competitive bid process among vetted buyers, negotiating the letter of intent and deal structure, and defending the agreed value through due diligence to closing.

This distinction can matter because a DSO or private equity buyer negotiates acquisitions routinely, while a practice owner usually sells once in a lifetime. Without representation, the owner faces a significant information gap on valuation, deal structure, buyer quality, and current market multiples. A dental-specific sell-side advisor helps close that gap by shaping the narrative around the practice’s profitability, creating competitive tension among multiple buyers, and serving as an advocate and buffer through a process that can otherwise break down at several points.

The difference in outcome between a single-offer, unrepresented sale and a structured, multi-buyer process with diligence-grade preparation can be substantial in both headline price and the quality of terms, equity structure, and post-close environment.

How are dental practice EBITDA multiples determined in 2026, and what factors move them up or down?

EBITDA multiples in dental M&A reflect a buyer’s view of the practice’s profitability, durability, and risk profile rather than a fixed schedule. The starting point is normalized EBITDA, which means reported earnings adjusted to replace owner compensation with a market-rate associate salary, add back personal and discretionary expenses, and remove non-recurring items. That process aims to show the maintainable cash flow a buyer is acquiring.

The multiple applied to that figure varies by practice size and structure. Larger, multi-location, and associate-led practices generally command higher multiples than single-doctor, owner-dependent practices. Several factors can compress a multiple, including high owner production concentration, significant Medicaid exposure, a short or non-assignable lease, or flat and declining revenue trends.

Factors that can support a premium multiple include a strong hygiene program generating recurring revenue, a diversified provider roster, clean and verifiable financials across multiple years, and a competitive bid process that creates tension among qualified buyers. Specialty also plays a role, as oral surgery, orthodontics, and pediatric dentistry often attract stronger multiples than general dentistry, subject to each practice’s specific characteristics.

For any individual practice, the multiple ultimately reflects its own numbers and market position, which a diligence-grade valuation is designed to clarify before going to market.

What are the risks of accepting an unsolicited DSO offer without running a competitive process?

Accepting a single unsolicited offer without market testing introduces several connected risks. First, the buyer has little reason to present their best offer when they believe they face no competition, so the initial number often serves as a starting point rather than a ceiling.

Second, once a letter of intent is signed and exclusivity begins, the seller’s leverage usually declines. Alternative buyers are no longer engaged, management time is committed to one path, and the buyer controls the pace and framing of due diligence. This stage is when re-trading, which means revising terms downward after the LOI is signed, most often occurs through EBITDA adjustments, working capital disputes, or shifts from cash at close to earnouts and equity.

Third, a single-offer process provides limited basis for evaluating whether the buyer is well-capitalized, well-run, or a good long-term partner for staff and patients. A competitive process with multiple vetted buyers can address all three risks by revealing market value, creating tension that helps keep buyers disciplined through diligence, and giving the seller a real choice among qualified partners.

How does rollover equity work in a DSO transaction, and how should sellers evaluate it?

Rollover equity means the selling dentist retains an ownership stake in the acquiring DSO instead of receiving the full purchase price in cash at closing. That equity can be structured at two levels. Joint-venture equity ties to the specific practice location and may generate distributions but usually has a lower ceiling on long-term upside. Holding-company equity ties to the entire DSO enterprise and typically generates no distributions, but if the DSO recapitalizes or sells to a larger buyer, the value can increase significantly.

As much as 40% of a DSO deal can be paid in equity rather than cash, which means the seller effectively becomes an investor in the DSO. Sellers often benefit from evaluating that equity as they would any investment by asking whether the DSO is profitable across existing locations, whether revenue is growing, whether the management team is experienced, and whether the private equity sponsor is well-capitalized with a history of successful exits.

A poorly run or undercapitalized DSO can put a large share of the seller’s proceeds at risk. Earnout provisions, which tie part of the purchase price to future performance metrics, add another layer of complexity because the seller’s ability to hit those targets can depend on factors outside their control after closing. Multi-year financial modeling across deal structures and time horizons, which a qualified sell-side advisor typically provides, can help clarify how rollover equity and earnouts affect the overall outcome.

When is the right time to engage a sell-side advisor, and how long does the process take?

Engaging a sell-side advisor earlier than expected often benefits practice owners. Many owners see advantages when they speak with an advisor before any direct conversations with buyers begin and well before signing a letter of intent. Verbal statements made during informal pre-LOI conversations can become anchors in formal negotiations, and once an LOI is signed, the seller’s leverage usually declines.

Early engagement allows the advisor to shape the narrative around the practice’s profitability from the outset and to run a structured process instead of reacting to a single inbound offer. A well-organized DSO transaction, from engagement through closing, often runs approximately six to ten months, depending on practice complexity and deal structure.

McLerran & Associates typically runs its competitive DSO bid process in about 45–60 days, generating around 10 offers, then narrowing to finalists and moving through due diligence to close. Preparation steps taken in the years before a sale, such as normalizing financials, reducing owner production concentration, strengthening the hygiene program, and ensuring lease terms are assignable, can meaningfully improve both the multiple achieved and the smoothness of the process.

If a sale is not imminent, McLerran can update a practice valuation at no charge a year after the initial evaluation, so owners can track their position in the market without committing to a specific timeline before they feel ready.